Shares of Bausch Health Companies Inc (BHC) surged 9.55% in after-hours trading following the release of its impressive second-quarter results and upgraded full-year guidance. The pharmaceutical company's performance exceeded analyst expectations, demonstrating resilience in key segments despite challenging market conditions.

Bausch Health reported Q2 revenue of $2.53 billion, marking a 5% year-over-year increase and surpassing the analyst consensus estimate of $2.481 billion. The company's adjusted EBITDA also saw a 6% growth, reaching $842 million. Notably, the SALIX segment experienced a 12% revenue increase, driven by Xifaxan's 10% growth, while the SOLTA MEDICAL segment posted an impressive 25% revenue rise, particularly strong in South Korea.

In response to the robust performance, Bausch Health raised its full-year 2025 revenue guidance to $10.0-$10.25 billion, up from previous estimates. The company also reaffirmed its adjusted EBITDA guidance between $3.485 billion and $3.635 billion. Additionally, Bausch Health announced plans for a $900 million debt repayment after the quarter-end and the acquisition of DURECT Corporation, further boosting investor confidence. Despite missing earnings per share estimates slightly, the overall positive outlook and strong revenue growth appear to have fueled the significant after-hours stock price surge.